We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

About us - Corporate Background | Grünenthal Ltd

The world needs better pain treatments


Pain is widely considered as one of the biggest problems in medicine today: a 2016 UK-based review indicates that an estimated 28 million adults in the UK suffer from chronic pain 1. Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.

1 Fayaz A, Croft P, Langford RM, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364.doi:10.1136/bmjopen-2015-010364

“Imagine going through your daily life where everything that you touch, or that touches you, where most every noise around you from a passing car to children playing, causes you pain. We will leave no stone unturned to help these patients.”

Gabriel Baertschi

Chief Executive Officer

Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.

 

Our ambition

By 2022, we will be a €2bn entrepreneurial, science-based company, specialising in pain and beyond and deliver five new medicines to patients with diseases with high unmet needs.
We are turbo-charging our delivery from our own research and collaborating with external partners.

 

Our strategy: leading with innovation

We focus our R&D activities on pain and have built up our portfolio with projects beyond pain and medical devices. This diversifies our risks and opens new markets for us.

 

“As a worldwide leader in pain management, we are looking for strategic partnerships in research and development to bring innovative solutions to patients with indications with high unmet medical needs. Innovation is at our core and as a fully integrated pharmaceutical company, we can offer support along the whole value chain – from drug development to commercialisation.”

Gabriel Baertschi

Chief Executive Officer

Get to know us

Grunenthal Ltd., UK, a subsidiary of Grunenthal GmBH, was established in 2004. With headquarters in Stokenchurch, Buckinghamshire, the company includes Regulatory, Medical Information, Sales and Marketing divisions as well as Market Access and Medical Science Liaison teams.

Grunenthal Ltd., UK currently markets medications for relief or management of moderate to severe pain including peripheral neuropathic pain to GPs, hospital doctors, pharmacists and nurses.

Grünenthal by the numbers

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 30 countries with affiliates in Europe, Latin America and the USA.

Leadership

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.

Join us

Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.


 

External Link:

You are now leaving the Grünenthal (UK) website. You will be re-directed to an external website. Grünenthal UK Ltd. accepts no responsibility for the content of other websites.

... Cancel ... Ok